Request Demo
Last update 01 Apr 2025
Coherent Biopharma Suzhou Co., Ltd.
Startups
|
Holding Company | Joint Venture Company | Subsidiary Company|
2016|
Jiangsu Sheng, China
| 100-250
| Last update 01 Apr 2025
Overview
Basic Info
Introduction Coherent Biopharma Suzhou Co. Ltd. is a business that specializes in producing biological products. It was established by Bao Hua Huang on March 3rd, 2016 and has its headquarters located in Suzhou, China. |
Tags
Neoplasms
Urogenital Diseases
Endocrinology and Metabolic Disease
Small molecule-drug conjugates
Proteolysis-targeting chimeras (PROTAC)
Monoclonal antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20231987
评价注射用CBP-1019在晚期胸部恶性肿瘤患者中安全性和耐受性、药代动力学及初步疗效的Ⅰ期临床研究
[Translation] A Phase I clinical study to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of CBP-1019 for injection in patients with advanced thoracic malignancies
CTR20231450
评价注射用CBP-1019在晚期恶性实体瘤患者中安全性和耐受性、药代动力学及初步疗效的非随机、开放、首次用于人体的国际多中心Ⅰ/Ⅱ期临床研究
[Translation] A non-randomized, open-label, first-in-human, international, multicenter Phase I/II clinical study to evaluate the safety and tolerability, pharmacokinetics, and preliminary efficacy of CBP-1019 for injection in patients with advanced malignant solid tumors
NCT05830097
An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
100 Clinical Results associated with Coherent Biopharma Suzhou Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Coherent Biopharma Suzhou Co., Ltd.
Login to view more data
100 Translational Medicine associated with Coherent Biopharma Suzhou Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 04 Apr 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
5
Preclinical
IND Application
1
1
Phase 1
Phase 2
1
1
Phase 3
Other
20
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free